BioCardia Inc. (BCDA) Next Earnings Date & Expected ±12.5% Move

Per the Roarable RQD rating, BCDA scores 38 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow."

• Fundamental Cash Engine (8 / 20): Per the Roarable RQD rating, ROIC is -35% and FCF yield is 0%. For an investor, this indicates the business is not currently generating returns on invested capital or free cash, so any valuation rests on future outcomes rather than present earnings.
• Whale 13F Flow (6 / 20): Per the Roarable RQD rating, institutional accumulation and options positioning score weakly. Institutional support is a potential upside driver; its absence limits confidence in near-term demand for the shares.
• Insider Conviction (5 / 20): Per the Roarable RQD rating, SEC Form 4 and Congressional PTR cluster flow score weakly. Per the news wire, a single small CEO share purchase appears in the headlines, but the rating does not treat it as a cluster signal.
• Macro Regime Fit (9 / 20): Per the Roarable RQD rating, beta is 1.0 and sector sensitivity is scored as a moderate weakness. This means price movement is not dampened relative to the market.
• Forensic Balance Sheet (10 / 20): Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. These readings signal financial fragility and weak fundamental quality, which is a key valuation tradeoff: the low share price and small market capitalization reflect this risk profile.

Overall, for a prospective investor evaluating the stock today, the rating points to a high-risk, pre-profit profile where upside depends on catalysts (see news wire) rather than current cash generation.

Per the SEC financials, operating and net losses persist across all three reported periods, and the market data shows a 0% gross, operating, and net margin with ROIC of -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Reported cash was $2.5M in FY 2025 and $2.4M in FY 2024, against FCF outflows of $-7.4M and $-7.9M, respectively. Balance sheet posture is therefore thin relative to annual cash burn, with debt reported as N/A.

Per the recent news wire, the main items are:

• A report that the CEO bought $475 in BCDA shares (YELLOW, MARKET WIRE).
• A report that the FDA agreed the heart-failure trial may support approval of its cell treatment (YELLOW, MARKET WIRE).
• A report of an FDA procedural step, with the stock up 6% pre-market (YELLOW, MARKET WIRE).
• A report that the FDA accepted the Helix Catheter De Novo pre-submission for marketing clearance (RED, RISK WATCH).
• A report of a CEO purchase of 500 shares at $0.95 across two purchases (YELLOW, MARKET WIRE).
• A report that a heart-treatment device has data from 15 trials and nearly 500 patients, with its FDA package accepted (YELLOW, MARKET WIRE).

Per the Butterfly Supply-Chain Graph, supply chain is NONE, with no butterfly links and no proprietary signals.

• What is the company's revenue model and expected timing of any commercial revenue, given $0.0M reported revenue?
• What is the current cash runway against the reported annual free cash outflows of $-7.4M (FY 2025)?
• What is the status and timing of the Helix Catheter marketing clearance process referenced in the news wire?
• Is any debt outstanding, given debt is reported as N/A across all periods?
• What are the precise terms and size of the insider share purchases referenced in the news wire?